MP0274-CP101: A phase 1, first-in-human, single-arm, multicenter, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors

Category Primary study
JournalCancer Research
Year 2018
This article has no abstract
Epistemonikos ID: d1b58f8d085166a73066e07d99d0ac3e5322783c
First added on: Feb 09, 2025